CA-TRACKFORCE-VALIANT
29.6.2022 16:02:08 CEST | Business Wire | Press release
Trackforce Valiant , a leading provider of security workforce management solutions, today announced the acquisition of TrackTik Software , one of the most innovative and fastest growing cloud-based security workforce management providers. The combination of these two companies has created a new dominant market leader in providing visibility and control for the physical security workforce.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005064/en/
“We are very excited to welcome TrackTik into the Trackforce Valiant family,” said Trevor Campion, CEO of Trackforce Valiant. “Now more than ever, we believe in the importance of providing the right security solutions for companies of all sizes and business needs. The addition of TrackTik enables us to provide a wide range of technology options that are purpose-built for the unique needs of physical security operations.”
TrackTik was founded in 2013 with the mission of providing a complete set of tools through easy-to-use software and taking the fear out of technology in order to put it to work for security workforce management. From their origins in Montreal, Canada, TrackTik provides solutions to over 35 countries across 6 continents and has been steadily innovating the way companies leverage workforce technology for security operations. The platform provides a full suite of applications, combining the needs of back-office administration to front line security operations.
As a result of this new venture, physical security companies now can leverage the combined best practices of two leading security workforce management providers, providing multiple options for how they can manage security operations. Additionally, the combined technology teams of Trackforce Valiant and TrackTik Software will enable the company to further innovate and enhance their solutions further than any other software provider in the industry.
“The physical security market continues to grow, and with that so does the need for solutions that can grow with them,” said Simon Ferragne, CEO of TrackTik. “This acquisition positions us as the dominant leader for security workforce technology, and we are thrilled to work together to continue our mission to build innovative, leading-edge solutions for our customers.”
Both companies will continue to maintain operations in service of their customers and partners, with Trevor Campion overseeing the combined organization as CEO, and Simon Ferragne, TrackTik’s CEO, entering the role of CTO. Simon Ferragne and TrackTik’s investors, CDPQ Investissements, Georgian, Klass Capital, Inovia Capital, Intercap, and Schauer Ventures have reinvested a portion of their proceeds in the newly combined entity to help foster continued growth in the company. TrackTik will continue to operate and maintain its presence in Quebec as one of Canada’s top small and medium employers. Trackforce Valiant and TrackTik will collaborate on developing and innovating security solutions that include Time and Labor Management, Guard Touring, Incident Management, Dispatch and Mobile Patrol, as well as Billing and Payroll management.
About Trackforce Valiant
Trackforce Valiant is a leader in complete security workforce management solutions. More than 300,000 professionals at over 30,000 customer sites in 45 countries use Trackforce Valiant every day to ensure the delivery of reliable security services, improve operational efficiency and optimally manage their human capital. For nearly 30 years, Trackforce Valiant has provided fully integrated security solutions to its partners and customers. Thanks to its security expertise and state-of-the-art information systems technology, Trackforce Valiant proudly offers the most effective solutions available on the market. Clients include the world's leading security guard service providers, as well as major airports, universities, and corporations across the globe. Additional information is available at https://www.trackforcevaliant.com .
About TrackTik
Founded in 2013, TrackTik is a privately-owned, VC-backed Canadian scale-up of 200+ employees providing a cloud-based workforce management solution in the physical security industry. Headquartered in Montreal, with offices in the UK and a presence in various provinces in Canada and the Netherlands, TrackTik serves 780 customers in more than 35 countries. TrackTik quickly established itself as a market leader with the mission to seamlessly connect humans, workflows, and systems to deliver a better way of working to the physical security workforce. TrackTik’s integrated suite of automated tools fluidly connects frontline operations and back-office management allowing managers to follow the progression of field workers, reduce manual tasks, lower cost, glean actionable insights from data to demonstrate value, promote operational efficiency and boost productivity, job satisfaction, and retention. Additional information is available at https://www.tracktik.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220629005064/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
